Zinbryta’s Risks Outweigh Benefits, EMA Review Determines

The EMA’s Pharmacovigilance Risk Assessment Committee released the findings of its review of Biogen and AbbVie’s multiple sclerosis medication Zinbryta (daclizumab beta), saying the drug poses a risk of serious and potentially fatal immune reactions that impact the brain, liver and other organs.

Although the two companies withdrew the medication from the global market over its adverse events, the EMA’s findings are relevant to patients, as they could be at risk from the start of treatment and for several months after ending treatment.

The agency recommended that healthcare professionals monitor patients who have been treated with the medication.